Actively Recruiting
Hepatocellular Carcinoma Identification Using Delta-HLD
Led by Epiliquid Holding, Inc · Updated on 2025-09-09
200
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
CONDITIONS
Official Title
Hepatocellular Carcinoma Identification Using Delta-HLD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed hepatocellular carcinoma (HCC) or clinically confirmed liver cirrhosis without HCC
- Willing and able to provide informed consent
- Availability of paired plasma and liver tissue samples
You will not qualify if you...
- Presence of other active cancers
- Prior liver transplantation
- Known hereditary cancer syndromes
- Recent chemotherapy or antiviral treatment within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Epiliquid
Mendoza, Argentina, 5500
Actively Recruiting
Research Team
D
Dr. Victoria Bocanegra, MD, PhD.
CONTACT
D
Dr. Emanuel Campoy, PhD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here